


CLAIMS

WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:



Formula (I):

wherein:

R¹ is H or -(C₁-C₆)alkyl optionally substituted with one, two, or three R^{1a}.

each R^{1a} is independently halogen, -CN, -OR^a, -SR^a, -NR^cR^d, -NO₂, -C(=O)R^b, -NR^aC(=O)R^b, -

$$\text{C(=O)OR}^a, -\text{C(=O)NR}^c\text{R}^d, -\text{NR}^a\text{C(=O)NR}^c\text{R}^d, -\text{S(=O)}_2\text{R}^b, -\text{S(=O)R}^b, -\text{S(=O)}_2\text{NR}^c\text{R}^d, -$$
$$\text{S(=O)NR}^{\text{c}}\text{R}^{\text{d}}, -\text{NR}^{\text{a}}\text{S(=O)}_2\text{R}^{\text{b}}, -\text{NR}^{\text{a}}\text{S(=O)}_2\text{NR}^{\text{c}}\text{R}^{\text{d}}, -\text{NR}^{\text{a}}\text{OR}^{\text{a}}, -\text{NR}^{\text{a}}\text{C(=O)NR}^{\text{a}}\text{OR}^{\text{a}}, -\text{O}(\text{C}_1-$$

C₆alkylene-NR^cR^d, -NR^aC(=NR^c)R^a, -C(=NR^a)NR^cR^d, -NR^aC(=NR^a)NR^cR^d, cycloalkyl,

heterocycloalkyl, aryl, or heteroaryl; or two R^{1a} on the same carbon are taken together to form an oxo;

R² is H, -NR^cR^d, or -(C₁-C₆)alkyl optionally substituted with one, two, or three R^{2a};

each R^{2a} is independently halogen, -CN, -OR^a, -SR^a, -NR^cR^d, -NO₂, -C(=O)R^b, -NR^aC(=O)R^b, -

$$\text{C(=O)OR}^a, -\text{C(=O)NR}^c\text{R}^d, -\text{NR}^a\text{C(=O)NR}^c\text{R}^d, -\text{S(=O)}_2\text{R}^b, -\text{S(=O)R}^b, -\text{S(=O)}_2\text{NR}^c\text{R}^d, -$$
$$\text{S(=O)NR}^c\text{R}^d, -\text{NR}^a\text{S(=O)}_2\text{R}^b, -\text{NR}^a\text{S(=O)}_2\text{NR}^c\text{R}^d, -\text{NR}^a\text{OR}^a, -\text{NR}^a\text{C(=O)NR}^a\text{OR}^a, -\text{O(C}_1-$$

C₆alkylene-NR^cR^d, -NR^aC(=NR^c)R^a, -C(=NR^a)NR^cR^d, -NR^aC(=NR^a)NR^cR^d, cycloalkyl,

heterocycloalkyl, aryl, or heteroaryl; or two R^{2a} on the same carbon are taken together to form an oxo;

R³ is H, -(C₃-C₆)cycloalkyl, or -(C₁-C₆)alkyl optionally substituted with one, two, or three R^{3a},

each R^{3a} is independently halogen, -CN, -OR^a, -SR^a, -NR^cR^d, -NO₂, -C(=O)R^b, -NR^aC(=O)R^b, -

$$\text{C(=O)OR}^a, -\text{C(=O)NR}^c\text{R}^d, -\text{NR}^a\text{C(=O)NR}^c\text{R}^d, -\text{S(=O)}_2\text{R}^b, -\text{S(=O)R}^b, -\text{S(=O)}_2\text{NR}^c\text{R}^d, -$$
$$\text{S(=O)NR}^c\text{R}^d, -\text{NR}^a\text{S(=O)}_2\text{R}^b, -\text{NR}^a\text{S(=O)}_2\text{NR}^c\text{R}^d, -\text{NR}^a\text{OR}^a, -\text{NR}^a\text{C(=O)NR}^a\text{OR}^a, -\text{O(C}_1-$$

C₆alkylene-NR^cR^d, -NR^aC(=NR^c)R^a, -C(=NR^a)NR^cR^d, -NR^aC(=NR^a)NR^cR^d, cycloalkyl,

heterocycloalkyl, aryl, or heteroaryl; or two R^{3a} on the same carbon are taken together to form an oxo;

R⁴ is H or -(C₁-C₆)alkyl;

X is (C₁-C₆)alkylene, (C₂-C₆)alkenylene, (C₂-C₆)alkynylene, (C₃-C₇)cycloalkylene, (C₂-C₇)heterocycloalkylene, arylene, or heteroarylene; wherein the alkylene, alkenylene, alkynylene, cycloalkylene, heterocycloalkylene, arylene, and heteroarylene is optionally substituted with one, two, or three R^X;

each R^X is independently halogen, -CN, -OR^a, -NR^cR^d, -NO₂, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^d, -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₃-C₇)cycloalkyl, or -(C₂-C₇)heterocycloalkyl; or two R^X on the same carbon are taken together to form an oxo;

Y is bond, -O-, -S-, (C₁-C₆)alkylene, (C₂-C₆)alkenylene, (C₂-C₆)alkynylene, (C₃-C₇)cycloalkylene, (C₂-C₇)heterocycloalkylene, arylene, or heteroarylene; wherein the alkylene, alkenylene, alkynylene, cycloalkylene, heterocycloalkylene, arylene, and heteroarylene is optionally substituted with one, two, or three R^Y;

each R^Y is independently halogen, -CN, -OR^a, -NR^cR^d, -NO₂, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^d, -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₃-C₇)cycloalkyl, or -(C₂-C₇)heterocycloalkyl; or two R^Y on the same carbon are taken together to form an oxo;

Z is H, halogen, -CN, -OR¹⁰, -SR¹⁰, -NR¹²R¹³, -C(=O)R¹¹, -C(=O)OR², -C(=O)NR¹²R¹³, -(C₁-C₁₂)alkyl, -(C₁-C₁₂)heteroalkyl, -(C₁-C₁₂)haloalkyl, -(C₁-C₁₂)hydroxyalkyl, -(C₁-C₁₂)aminoalkyl, -(C₂-C₁₂)alkenyl, -(C₂-C₁₂)alkynyl, -(C₃-C₉)cycloalkyl, -(C₂-C₇)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one, two, or three R^Z;

each R^Z is independently halogen, -CN, -OR¹⁰, -NR¹²R¹³, -NO₂, -C(=O)R¹¹, -C(=O)OR¹⁰, -C(=O)NR¹²R¹³, -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₇)cycloalkyl, or -(C₂-C₇)heterocycloalkyl; or two R^Z on the same carbon are taken together to form an oxo;

each R¹⁰ is independently H, -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₇)cycloalkyl, (C₂-C₇)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three R^{10a};

each R^{10a} is independently halogen, -CN, -OR^a, -NR^cR^d, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^d, -(C₁-C₆)alkyl, or -(C₁-C₆)haloalkyl; or two R^{10a} on the same carbon are taken together to form an oxo;

each R¹¹ is independently -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₇)cycloalkyl, (C₂-C₇)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl,

heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three R^{11a};

each R^{11a} is independently halogen, -CN, -OR^a, -NR^cR^d, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^d, -(C₁-C₆)alkyl, or -(C₁-C₆)haloalkyl; or two R^{11a} on the same carbon are taken together to form an oxo; each R¹² and R¹³ is independently H, -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₇)cycloalkyl, (C₂-C₇)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three R^{12a};

or R¹² and R¹³ are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R^{12b};

each R^{12a} is independently halogen, -CN, -OR^a, -NR^cR^d, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^d, -(C₁-C₆)alkyl, or -(C₁-C₆)haloalkyl; or two R^{12a} on the same carbon are taken together to form an oxo; each R^{12b} is independently halogen, -CN, -OR^a, -NR^cR^d, -C(=O)R^b, -C(=O)OR^a, -C(=O)NR^cR^d, -(C₁-C₆)alkyl, or -(C₁-C₆)haloalkyl; or two R^{12b} on the same carbon are taken together to form an oxo; each R^a is independently H, -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₇)cycloalkyl, (C₂-C₇)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three halogen, -CN, -OH, -OMe, -NH₂, -C(=O)Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH₂, or -(C₁-C₆)alkyl;


each R^b is independently -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₇)cycloalkyl, (C₂-C₇)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three halogen, -CN, -OH, -OMe, -NH₂, -C(=O)Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH₂, or -(C₁-C₆)alkyl; and

each R^c and R^d is independently H, -(C₁-C₆)alkyl, -(C₁-C₆)haloalkyl, -(C₁-C₆)heteroalkyl, -(C₁-C₆)hydroxyalkyl, -(C₁-C₆)aminoalkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₇)cycloalkyl, (C₂-C₇)heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally independently substituted with one, two, or three halogen, -CN, -OH, -OMe, -NH₂, -C(=O)Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH₂, or -(C₁-C₆)alkyl;

or R^c and R^d are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three oxo, halogen, -CN, -OH, -OMe, -NH₂, -C(=O)Me, -C(=O)OH, -C(=O)OMe, -C(=O)NH₂, or -(C₁-C₆)alkyl.


2. The compound of claim 1, wherein R² is H or -(C₁-C₆)alkyl.
3. The compound of claim 1 or 2, wherein R² is H.

4. The compound of any one of claims 1-3, wherein R^3 is H or $-(C_1-C_6)alkyl$.
5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^3 is $-(C_1-C_6)alkyl$.
6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^3 is methyl.
7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^4 is H.
8. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^4 is methyl.
9. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof; wherein the compound has the structure of Formula (Ia):



Formula (Ia)

10. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof; wherein the compound has the structure of Formula (Ib):





Formula (Ib).

11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 is $-(C_1-C_6)alkyl$ optionally substituted with one, two, or three R^{1a} .
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 is $-(C_1-C_6)alkyl$ substituted with one R^{1a} .
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^{1a} is independently halogen, $-CN$, $-OR^a$, $-NR^cR^d$, $-NR^cC(=O)R^b$, $-NR^cC(=O)NR^cR^d$, $-NR^cS(=O)_2R^b$, or $-NR^cS(=O)_2NR^cR^d$.
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^{1a} is independently $-NR^cR^d$ or $-NR^cS(=O)_2NR^cR^d$.
15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^{1a} is independently $-NR^cR^d$.
16. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^{1a} is independently $-NR^cS(=O)_2NR^cR^d$.
17. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 is $-CH_2CH_2NH_2$, $-CH_2CH_2NHSO_2NH_2$ or $-CH_2NHSO_2NH_2$.
18. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 is $-CH_2CH_2NH_2$.
19. The compound of any one of claims 1-14 or 16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 is $-CH_2CH_2NHSO_2NH_2$.
20. The compound of any one of claims 1-14 or 16, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^1 is $-CH_2NHSO_2NH_2$.
21. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is $(C_2-C_7)heterocycloalkylene$ or $heteroarylene$; each optionally substituted with one, two, or three R^X .
22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is $(C_2-C_7)heterocycloalkylene$ optionally substituted with one, two, or three R^X .
23. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X is $heteroarylene$ optionally substituted with one, two, or three R^X .
24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^X is independently halogen, $-OR^a$, $-NR^cR^d$, $-(C_1-C_6)alkyl$, or $-(C_1-C_6)haloalkyl$; or two R^X on the same carbon are taken together to form an oxo.
25. The compound of any one of claims 1-24, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^X is independently $-NR^cR^d$ or $-(C_1-C_6)alkyl$; or two R^X on the same carbon are taken together to form an oxo.


26. The compound of any one of claims 1-25, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Y is $-(C_2-C_7)$ heterocycloalkylene or arylene; each optionally substituted with one, two, or three R^Y .
27. The compound of any one of claims 1-26, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Y is arylene optionally substituted with one, two, or three R^Y .
28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^Y is independently halogen, $-OR^a$, $-NR^cR^d$, $-(C_1-C_6)$ alkyl, or $-(C_1-C_6)$ haloalkyl; or two R^Y on the same carbon are taken together to form an oxo.
29. The compound of any one of claims 1-28, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is H, halogen, $-CN$, $-OR^{10}$, $-SR^{10}$, $-NR^{12}R^{13}$, $-C(=O)R^{11}$, $-C(=O)OR^2$, $-C(=O)NR^{12}R^{13}$, $-(C_1-C_{12})$ alkyl, $-(C_1-C_{12})$ heteroalkyl, $-(C_1-C_{12})$ haloalkyl, $-(C_1-C_{12})$ hydroxyalkyl, $-(C_1-C_{12})$ aminoalkyl, $-(C_2-C_{12})$ alkenyl, $-(C_2-C_{12})$ alkynyl, $-(C_3-C_7)$ cycloalkyl, $-(C_2-C_7)$ heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are optionally substituted with one, two, or three R^Z .
30. The compound of any one of claims 1-29, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is halogen, $-OR^{10}$, $-NR^{12}R^{13}$, $-(C_1-C_{12})$ alkyl, $-(C_1-C_{12})$ heteroalkyl, $-(C_1-C_{12})$ haloalkyl, $-(C_1-C_{12})$ hydroxyalkyl, $-(C_1-C_{12})$ aminoalkyl, $-(C_3-C_9)$ cycloalkyl, or $-(C_2-C_7)$ heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl are optionally substituted with one, two, or three R^Z .
31. The compound of any one of claims 1-30, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-OR^{10}$, $-(C_1-C_{12})$ alkyl, $-(C_1-C_{12})$ haloalkyl, or $-(C_3-C_9)$ cycloalkyl; wherein the alkyl and cycloalkyl are optionally substituted with one, two, or three R^Z .
32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-OR^{10}$.
33. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_1-C_{12})$ alkyl optionally substituted with one, two, or three R^Z .
34. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_1-C_{12})$ alkyl.
35. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_1-C_{12})$ haloalkyl optionally substituted with one, two, or three R^Z .
36. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_1-C_{12})$ haloalkyl.
37. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_3-C_9)$ cycloalkyl optionally substituted with one, two, or three R^Z .

38. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_3-C_9)\text{cycloalkyl}$.
39. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_3-C_7)\text{cycloalkyl}$ optionally substituted with one, two, or three R^Z .
40. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein Z is $-(C_3-C_7)\text{cycloalkyl}$.
41. The compound of any one of claims 1-40, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^Z is independently halogen, $-\text{OR}^{10}$, $-\text{NR}^{12}\text{R}^{13}$, or $-(C_1-C_6)\text{alkyl}$.
42. The compound of any one of claims 1-41, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein each R^Z is independently $-(C_1-C_6)\text{alkyl}$.
43. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^{10} is $-(C_1-C_6)\text{alkyl}$, $-(C_1-C_6)\text{haloalkyl}$, or $-(C_3-C_7)\text{cycloalkyl}$.
44. The compound of any one of claims 1-43, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein R^{10} is $-(C_1-C_6)\text{alkyl}$ or $-(C_3-C_7)\text{cycloalkyl}$.
45. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein $-\text{X}-\text{Y}-\text{Z}$ is







46. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein -X-Y-Z is




47. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein -X-Y-Z is




48. The compound of any one of claims 1-20, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein -X-Y-Z is





49. The compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein -X-Y-Z is





50. A compound, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:































51. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:















52. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:












and

53. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:





54. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from the group consisting of:



55. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the compound is (8S,11S,14S)-18-hydroxy-11-methyl-14-[methyl-[(2S)-2-[[4-amino-2-(4-tert-butylphenyl)-6-methyl-pyrimidine-5-carbonyl]amino]-3-(sulfamoylamino)propanoyl]amino]-10,13-dioxo-3,17-bis[(2R)-3-amino-2-hydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaene-8-carboxylic acid.
56. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the compound is (8S,11S,14S)-18-hydroxy-11-methyl-14-[methyl-[(2S)-2-[[4-methyl-2-

- [4-(1-methylcyclopropyl)phenyl]pyrimidine-5-carbonyl]amino]-3-(sulfamoylamino)propanoyl]amino]-10,13-dioxo-3,17-bis[(2R)-3-amino-2-hydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaene-8-carboxylic acid.
57. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the compound is (8S,11S,14S)-18-hydroxy-11-methyl-14-[methyl-[(2S)-4-amino-2-[[4-amino-2-(4-tert-butylphenyl)-6-methyl-pyrimidine-5-carbonyl]amino]butanoyl]amino]-10,13-dioxo-3,17-bis[(2R)-3-amino-2-hydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaene-8-carboxylic acid.
 58. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the compound is (8S,11S,14S)-18-hydroxy-11-methyl-14-[methyl-[(2S)-4-amino-2-[[4-methyl-2-[4-(1-methylcyclopropyl)phenyl]pyrimidine-5-carbonyl]amino]butanoyl]amino]-10,13-dioxo-3,17-bis[(2R)-3-amino-2-hydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaene-8-carboxylic acid.
 59. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the compound is (8S,11S,14S)-18-hydroxy-11-methyl-14-[methyl-[(2S)-4-amino-2-[[2-(4-tert-butylphenyl)-4-amino-6-difluoromethyl-pyrimidine-5-carbonyl]amino]butanoyl]amino]-10,13-dioxo-3,17-bis[(2R)-3-amino-2-hydroxy-propoxy]-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaene-8-carboxylic acid.
 60. The compound of claim 50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the compound is (8S,11S,14S)-14-[[[(2S)-2-[[4-amino-2-(4-tert-butylphenyl)-6-(difluoromethyl)pyrimidine-5-carbonyl]amino]-3-(sulfamoylamino)propanoyl]-methyl-amino]-3,17-bis[(2R)-3-amino-2-hydroxy-propoxy]-18-hydroxy-11-methyl-10,13-dioxo-9,12-diazatricyclo[13.3.1.12,6]icosa-1(18),2(20),3,5,15(19),16-hexaene-8-carboxylic acid.
 61. A pharmaceutical composition comprising the compound of any one of claims 1-60, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
 62. Use of a compound of any one of claims 1-60, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, for preparation of a medicament for the treatment of a bacterial infection in a patient.
 63. A method of treatment of a bacterial infection in a mammal, comprising administering to the mammal an effective amount of a compound of any one of claims 1-60, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, to the mammal at a frequency and for a duration sufficient to provide a beneficial effect to the mammal.
 64. A method of treatment of a lepB-mediated infection in a mammal, comprising administering to the mammal an effective amount of a compound of any one of claims 1-60, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, to the mammal at a frequency and for a duration sufficient to provide a beneficial effect to the mammal.

65. The method of claim 63 or 64, wherein the bacterial infection is an infection involving *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, *Pseudomonas acidovorans*, *Pseudomonas alcaligenes*, *Pseudomonas putida*, *Stenotrophomonas maltophilia*, *Burkholderia cepacia*, *Aeromonas hydrophilia*, *Escherichia coli*, *Citrobacter freundii*, *Salmonella typhimurium*, *Salmonella typhi*, *Salmonella paratyphi*, *Salmonella enteritidis*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Enterobacter cloacae*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Serratia marcescens*, *Francisella tularensis*, *Morganella morganii*, *Proteus mirabilis*, *Proteus vulgaris*, *Providencia alcalifaciens*, *Providencia rettgeri*, *Providencia stuartii*, *Acinetobacter baumannii*, *Acinetobacter calcoaceticus*, *Acinetobacter haemolyticus*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*, *Yersinia intermedia*, *Bordetella pertussis*, *Bordetella parapertussis*, *Bordetella bronchiseptica*, *Haemophilus influenzae*, *Haemophilus parainfluenzae*, *Haemophilus haemolyticus*, *Haemophilus parahaemolyticus*, *Haemophilus ducreyi*, *Pasteurella multocida*, *Pasteurella haemolytica*, *Branhamella catarrhalis*, *Helicobacter pylori*, *Campylobacter fetus*, *Campylobacter jejuni*, *Campylobacter coli*, *Borrelia burgdorferi*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Legionella pneumophila*, *Listeria monocytogenes*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Kingella*, *Moraxella*, *Gardnerella vaginalis*, *Bacteroides fragilis*, *Bacteroides distasonis*, *Bacteroides 3452A* homolog group, *Bacteroides vulgatus*, *Bacteroides ovalus*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, *Bacteroides eggerthii*, *Bacteroides splanchnicus*, *Clostridium difficile*, *Mycobacterium tuberculosis*, *Mycobacterium avium*, *Mycobacterium intracellulare*, *Mycobacterium leprae*, *Corynebacterium diphtheriae*, *Corynebacterium ulcerans*, *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *Streptococcus pyogenes*, *Enterococcus faecalis*, *Enterococcus faecium*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus saprophyticus*, *Staphylococcus intermedius*, *Staphylococcus hyicus* subsp. *hyicus*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, or *Staphylococcus saccharolyticus*.
66. The method of any one of claims 63-65, wherein the bacterial infection is an infection involving *Acinetobacter baumannii*, *Klebsiella pneumoniae* or *Pseudomonas aeruginosa*.
67. The method of any one of claims 63-66, wherein the bacterial infection is an infection involving *Acinetobacter baumannii*.
68. The method of claim 63 or 64, wherein the bacterial infection is an infection involving a Gram-negative bacteria.
69. The method of any one of claims 63-68 further comprising administering a second therapeutic agent.
70. The method of claim 69, wherein the second therapeutic agent is not a SpsB or LepB inhibitor.
71. The method of claim 70, wherein the second therapeutic agent is an aminoglycoside antibiotic, fluoroquinolone antibiotic, β -lactam antibiotic, macrolide antibiotic, glycopeptide antibiotic,

rifampicin, chloramphenicol, fluoramphenicol, colistin, mupirocin, bacitracin, daptomycin, or linezolid.

72. The method of claim 70, wherein the second therapeutic agent is a β -lactam antibiotic.
73. The method of claim 72, wherein the β -lactam antibiotic is selected from penicillins, monobactams, cephalosporins, cephamycins, and carbapenems.
74. The method of claim 73, wherein the β -lactam antibiotic is selected from Azlocillin, Amoxicillin, Ampicillin, Doripenem, Meropenem, Biapenem, Cefamandole, Imipenem, Mezlocillin, Cefmetazole, Cefprozil, Piperacillin/tazobactam, Carbenicillin, Cefaclor, Cephalothin, Ertapenem, Cefazolin, Cefepime, Cefonicid, Cefoxitin, Ceftazidime, Oxacillin, Cefdinir, Cefixime, Cefotaxime, Cefotetan, Cefpodoxime, Ceftizoxime, Ceftriaxone, Faropenem, Mecillinam, Methicillin, Moxalactam, Ticarcillin, Tomopenem, Ceftobiprole, Ceftaroline, Flomoxef, Cefiprome, and Cefozopran.
75. The method of any one of claims 63-74, further comprising administering a β -lactamase inhibitor.